Epidarex Portfolio News

26 Jun

30

Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

In All, Portfolio

Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy. Treatment-naïve patients with PNH show clinically meaningful improvements for all hematological parameters when treated with APL-2.   CRESTWOOD, Ky. and WALTHAM, Mass. —  Apellis Pharmaceuticals, Inc.  (Nasdaq:APLS),…

25 Jun

32

NodThera Secures £28 million ($40 million) Series A Financing

In All, Portfolio

NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation Cambridge, UK, 25 June 2018 – NodThera, a biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases…

21 Jun

22

AdoRx Therapeutics Announces Initial Funding of $10 million for the Discovery of New Cancer Therapeutics

In All, Portfolio

Edinburgh, Scotland, 21st June 2018 – AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that it has closed an initial $10 million investment round financed by Epidarex Capital and CRT Pioneer Fund (‘CPF’). AdoRx was…

09 May

15

IGEM Therapeutics Announces UK Government Funding to Develop a Novel IgE Antibody Targeting Solid Tumours

In All, Portfolio

£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM to progress second product candidate towards the clinic London, 9 May 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a…

24 Apr

21

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

In All, Portfolio

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration   Hamburg, 24th April 2018 – Topas Therapeutics GmbH (Topas), a Hamburg,…

18 Apr

21

Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock

In All, Portfolio

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its underwritten public offering of 5,500,000 shares of…

16 Apr

22

Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

In All, Portfolio

Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, KY. and WALTHAM, MA., April 16, 2018 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of…

12 Apr

28

Epidarex-Backed Enterprise Therapeutics Raises £29 million ($41 million USD) Funding

In All, Portfolio

Initially founded with capital from leading healthcare investor Epidarex Capital, Enterprise raises Series B round co-led by Versant Ventures and Novartis Venture Fund, with Forbion, Epidarex Capital and IP Group completing the syndicate Funding will advance pipeline of novel treatments for respiratory diseases into clinical…